الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> HCV>>Merimepodib

Merimepodib (Synonyms: VX-497)

رقم الكتالوجGC13522

Merimepodib (VX-497) هو مثبط غير تنافسي ويتم تناوله عن طريق الفم من نازعة هيدروجين الإينوزين أحادي الفوسفات (IMPDH) مع أنشطة واسعة النطاق مضادة للفيروسات

Products are for research use only. Not for human use. We do not sell to patients.

Merimepodib التركيب الكيميائي

Cas No.: 198821-22-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
101٫00
متوفر
1mg
44٫00
متوفر
5mg
102٫00
متوفر
10mg
168٫00
متوفر
25mg
313٫00
متوفر
50mg
447٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of Merimepodib

Merimepodib(VX-497) is a novel, noncompetitive and orally bioavailable inhibitor of Inosine monophosphate dehydrogenase (IMPDH) [1]. IMPDH is anenzymethat convertsinosine monophosphatetoxanthosine monophosphate. IMPDH is associated withcell proliferation, making it a possible target forcancerchemotherapy [2].

In vitro: VX-497 (MW 452.5) inhibited the proliferation of primary human, rat, mouse, and dog lymphocytes at concentrations of approximately 100 nM. The inhibitory effect of VX-497 on lymphocytes was reversed in the presence of exogenous guanosine, but not in the presence of adenosine or uridine, confirming that the antilymphocytic activity of VX-497 was specifically due to inhibition of IMPDH[1]. VX-497 was most potent against the first group of viruses on virus replication, which included HBV, HCMV, EMCV, and RSV, with IC50 values of 0.38, 0.80, 1.0, and 1.14 μM, respectively [3].

In vivo: Oral administration of VX-497 dose-dependently inhibited the primary IgM antibody response, with an ED50 value of approximately 30-35 mg/kg in mice. Single daily dosing of VX-497 was as effective as twice-daily dosing in this model of immune activation [1].In the skin transplant study, trunk skin grafts from Balb/c mice were grafted onto C57Bl/6 mice. Administration of VX-497 twice daily until day 10 significantly prolonged graft survival to 13.2 ± 1.2 (p < 0.001, Kaplan Meier Log-Rank test) days in the 50 mg/kg group and 13.9 ± 1.0 (p < 0.001) days in the 85 mg/kg group [4].

References:
[1]. Jain J1, Almquist SJ,Shlyakhter D,Harding MW. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.J Pharm Sci.2001 May;90(5):625-37.
[2]. Pimkin M1,Markham GD. Inosine 5'-monophosphate dehydrogenase.Adv Enzymol Relat Areas Mol Biol.2009;76:1-53.
[3]. Markland W1,McQuaid TJ,Jain J,Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.Antimicrob Agents Chemother.2000 Apr;44(4):859-66.
[4]. Decker CJ1,Heiser AD,Chaturvedi PR,Faust TJ,Ku G,Moseley S,Nimmesgern E. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.Drugs Exp Clin Res.2001;27(3):89-95.

Protocol of Merimepodib

Cell experiment:

The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM l-glutamine. EMCV is infected at 500 PFU/107 L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof.

References:

[1]. Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
[2]. Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66.
[3]. Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27(3):89-95.

Chemical Properties of Merimepodib

Cas No. 198821-22-6 SDF
المرادفات VX-497
Chemical Name [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
Canonical SMILES COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4
Formula C23H24N4O6 M.Wt 452.46
الذوبان ≥ 45.2mg/mL in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Merimepodib

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.2101 mL 11.0507 mL 22.1014 mL
5 mM 0.442 mL 2.2101 mL 4.4203 mL
10 mM 0.221 mL 1.1051 mL 2.2101 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of Merimepodib

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for Merimepodib

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Merimepodib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.